Video Presentation - VT28
2590
Dr.Sunayana N Murthy
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 2590 | Dr.Sunayana N Murthy | sunayananm@gmail.com | 9945042064 |
Anterior Segment
CRACKING THE CORNEAL FIBROSIS - LOSARTAN MAGIC!
To assess clinical and imaging outcomes of corneal scars treated with topical losartan (0.8 mg/mL) for 6 months, targeting TGF-β–mediated fibrosis.In this study, 45 eyes were evaluated with etiologies mainly scars post fungal keratitis, post corneal tear and post refractive surgery. Losartan stock was aseptically prepared, 0.2 µm filter-sterilized, labelled, and sterility-verified before use at our lab. Patients received losartan drops 6 times daily for 6 months. Drop comfort and side effects were recorded.At 3 months, mean BCVA improved from 0.25 ± 0.17 to 0.17 ± 0.09 logMAR. Visual acuity improved in 35 eyes, stable in 10. OCT showed reduced scar depth and densitometry in 35 eyes. No significant side effects were noted.Topical losartan may reduce corneal fibrosis by inhibiting TGF-β pathways, improving clarity and scar depth.Losartan could serve as an affordable adjunctive therapy to enhance visual outcomes in patients with ocular scars.
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 865 | Prof.Rohit Shetty | drrohitshetty@yahoo.com | 9611102568 |
| Non Member | Dr.swaminathan setu | swaminathansethu@narayananethralayna.com | 9840343313 |